No annual revenue total was found in ANNEXON, INC.'s SEC filings.
Annexon, Inc. (ANNX) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$186.5 million. As of Jun 30, 2026 it held $209.2 million in cash and investments and $24.7 million in total debt.
Revenue
—
Net income (TTM)
$-202.67M
-8.4% vs year-ago TTM
Operating cash flow (TTM)
$-193.03M
-23.6% vs year-ago TTM
Free cash flow (TTM)
$-193.22M
-23.7% vs year-ago TTM
EPS (TTM)
$-1.13
+10.5% vs year-ago TTM
Dividend per share
$0.00
Shares outstanding
149.36M
+36.6% vs prior year
Net cash
$184.59M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ANNX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Brisbane, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1528115
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$216.4M | -$154.1M | -$143.7M | -$145.6M | -$130.7M |
| Net income | -$206.7M | -$138.2M | -$134.2M | -$141.9M | -$130.3M |
| Diluted EPS | -$1.34 | -$1.01 | -$1.77 | -$2.60 | — |
| Operating cash flow | -$186.4M | -$118.0M | -$121.1M | -$116.3M | -$106.1M |
| Free cash flow | -$186.5M | -$118.0M | -$121.3M | -$122.8M | -$107.8M |
| Total assets | $277.6M | $350.1M | $297.7M | $285.1M | $287.0M |
| Total liabilities | $65.9M | $57.0M | $47.1M | $53.9M | $55.1M |
| Stockholders' equity | $211.6M | $293.1M | $250.6M | $231.2M | $231.9M |
| Cash and investments | $238.3M | $312.0M | $259.7M | $242.7M | $242.7M |
| Total debt | $26.2M | $29.0M | $31.4M | $32.9M | $34.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Other events
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Material agreement, New debt, Other events
|
Jul 30, 2026 | Jul 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 12, 2026 | Jun 11, 2026 |
All 522 Annexon, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.